India's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...

Brokerages are selectively backing consumer, logistics, and e-commerce firms with strong growth prospects. Citi initiates coverage on Meesh...

Indian stock markets saw a subdued trading session on Tuesday, with the Sensex and Nifty experiencing minor dips, primarily due to losses i...

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...

Brokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...

Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...

Foreign investors remain cautious about Indian stocks, despite some cash market buying. Their derivative bets show lingering doubt, influen...

Indian markets concluded the week on a strong note, driven by consistent buying interest and a significant drop in volatility. The Nifty in...

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...

Brokerage views on Indian equities are mixed as Morgan Stanley raises Nykaa's target price on ambitious FY30 growth plans. Conversely, conc...

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...

From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

Brokerages show selective optimism amidst market jitters. Goldman Sachs backs Shyam Metalics & Energy with a 10% upside target, anticipatin...

As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

Aman Chowhan of Abakkus Asset Manager highlights crude oil as the dominant macro risk, potentially impacting corporate earnings by 100-200 ...

Easing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...